Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants.
Whether gestational immunization of HIV-infected mothers with the 23-valent pneumococcal polysaccharide vaccine (PPV) confers maternal and infant early life, passive protection is not known. We evaluated safety, immunogenicity and placental transfer of antibodies in 44 HIV-infected women. Pneumococcal IgG antibodies against serotypes 1, 3, 5, 6B, 9V, and 14 were measured in mothers (pre-vaccination and at delivery), and infants (at birth, 1, 2, 3, and 6 months). PPV was safe and immunogenic in mothers. Newborns received 46-72% of maternal antibody titers. Overall, infants had antibody levels lower than protective by 2 months of age. Alternative pneumococcal vaccination of HIV-infected pregnant women should be explored with the aim of prolonging passive protection in their infants.
Almeida
Volia De Carvalho
Vde C
Department of Medicine, Biological and Health Sciences Center, Federal University of São Carlos, CEP 13565-905 São Carlos, Brazil. volia@ufscar.br
Mussi-Pinhata
Marisa Márcia
MM
De Souza
Cleonice Barbosa Sandoval
CB
Kubo
Christina Arslanian
CA
Martinez
Edson Zangiacomi
EZ
Carneiro-Sampaio
Magda Maria
MM
Duarte
Geraldo
G
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000009:adverse effects / Q000276:immunology*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D037841:Pregnant People; D055815:Young Adult
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines